title: Prostate cancer: Testosterone-guided ADT for prostate cancer.
authors.affiliation: Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Urasa 4132, Minamiuonumashi, Niigata 949-7302, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nishiyama
authors.affiliation: Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Urasa 4132, Minamiuonumashi, Niigata 949-7302, Japan.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Hoshii
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D019468:Disease Management; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone
references.citation: Sci Rep. 2013;3:1528
references.pmid: 23524847
references.citation: J Urol. 2007 Jun;177(6):2132-5; discussion 2135
references.pmid: 17509298
references.citation: J Clin Endocrinol Metab. 2010 Oct;95(10):4542-8
references.pmid: 20926540
references.citation: Prostate. 2016 Feb;76(2):235-42
references.pmid: 26768279
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references.pmid: 18309951
references.citation: Urology. 2000 Dec 20;56(6):1021-4
references.pmid: 11113751
references.citation: J Clin Oncol. 2015 Apr 1;33(10):1151-6
references.pmid: 25732157
references.citation: J Urol. 2003 Jan;169(1):251-5
references.pmid: 12478147
references.citation: J Urol. 2007 Oct;178(4 Pt 1):1290-5
references.pmid: 17698136